Innovent Biologics

Takeda R&D Exec Explains How $1.2B Deal Could Become One of the Biggest Bargains in Drug History

Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this week during the annual J.P. Morgan Healthcare Conference in San Francisco. Takeda President, Research and Development, Andy Plump talked to MedCity News about what sets the Japanese pharma company’s newly licensed drug apart.

By Frank Vinluan

BioPharma, Pharma

Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs

Takeda’s agreement with Innovent Biologics brings cancer drugs that could become contributors to a portfolio that’s facing the patent cliff. The pharmaceutical giant’s strategy for finding new blockbuster prospects spans internally discovered drugs and in-licensed assets.

By Frank Vinluan